{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:56:03Z","timestamp":1792540563141,"version":"4.5.0"},"reference-count":152,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202208320068"],"award-info":[{"award-number":["202208320068"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Since the discovery of penicillin, \u03b2-lactam antibiotics have commonly been used to treat bacterial infections. Unfortunately, at the same time, pathogens can develop resistance to \u03b2-lactam antibiotics such as penicillins, cephalosporins, monobactams, and carbapenems by producing \u03b2-lactamases. Therefore, a combination of \u03b2-lactam antibiotics with \u03b2-lactamase inhibitors has been a promising approach to controlling \u03b2-lactam-resistant bacteria. The discovery of novel \u03b2-lactamase inhibitors (BLIs) is essential for effectively treating antibiotic-resistant bacterial infections. Therefore, this review discusses the development of innovative inhibitors meant to enhance the activity of \u03b2-lactam antibiotics. Specifically, this review describes the classification and characteristics of different classes of \u03b2-lactamases and the synergistic mechanisms of \u03b2-lactams and BLIs. In addition, we introduce potential sources of compounds for use as novel BLIs. This provides insights into overcoming current challenges in \u03b2-lactamase-producing bacteria and designing effective treatment options in combination with BLIs.<\/jats:p>","DOI":"10.3390\/antibiotics13030260","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T09:32:30Z","timestamp":1710495150000},"page":"260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Role of \u03b2-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-3926","authenticated-orcid":false,"given":"Song","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liao","sequence":"additional","affiliation":[{"name":"Future Food Laboratory, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Ding","sequence":"additional","affiliation":[{"name":"Future Food Laboratory, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China"},{"name":"Department of Food Science and Nutrition, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-009X","authenticated-orcid":false,"given":"Juhee","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea"},{"name":"Future Food Laboratory, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/1751-7915.12783","article-title":"Microbial approaches for targeting antibiotic-resistant bacteria","volume":"10","author":"Wong","year":"2017","journal-title":"Microb. Biotechnol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1073\/pnas.1503141112","article-title":"Global trends in antimicrobial use in food animals","volume":"112","author":"Brower","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jiph.2016.08.007","article-title":"Antibiotic resistance","volume":"10","author":"Frieri","year":"2017","journal-title":"J. Infect. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12275-020-0285-z","article-title":"Recent advances in the development of beta-lactamase inhibitors","volume":"58","author":"Jalde","year":"2020","journal-title":"J. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","article-title":"The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis","volume":"32","author":"Sauvage","year":"2008","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1574-6976.2007.00095.x","article-title":"Penicillin-binding proteins and beta-lactam resistance","volume":"32","author":"Zapun","year":"2008","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between beta-lactamases and new beta-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2017.21550","article-title":"The drug-resistant bacteria that pose the greatest health threats","volume":"543","author":"Willyard","year":"2017","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"beta-Lactams and beta-Lactamase Inhibitors: An Overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/13543776.2020.1767070","article-title":"A 2018\u20132019 patent review of metallo beta-lactamase inhibitors","volume":"30","author":"Reddy","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/antibiotics3020193","article-title":"beta-Lactam Antibiotics Renaissance","volume":"3","author":"Qin","year":"2014","journal-title":"Antibiotics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1365-2958.1991.tb00821.x","article-title":"Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae","volume":"5","author":"Laible","year":"1991","journal-title":"Mol. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1128\/AAC.49.4.1432-1440.2005","article-title":"Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: Natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins","volume":"49","author":"Mussi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/AAC.32.8.1267","article-title":"Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability","volume":"32","author":"Studemeister","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/AAC.49.8.3198-3202.2005","article-title":"Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii","volume":"49","author":"Heritier","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jgar.2013.01.005","article-title":"Carbapenemases: Partners in crime","volume":"1","author":"Bush","year":"2013","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/acs.jmedchem.9b01279","article-title":"beta-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs","volume":"63","author":"Rodriguez","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1111\/jam.15130","article-title":"Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: A scientific review","volume":"131","author":"Nguyen","year":"2021","journal-title":"J. Appl. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa\u2014An emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace","volume":"215","author":"Logan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14787210.2023.2223977","article-title":"Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: A clinical narrative review","volume":"21","author":"Sorli","year":"2023","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/gutjnl-2016-311868","article-title":"First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis","volume":"67","author":"Yeo","year":"2018","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00416-17","DOI":"10.1128\/AEM.00416-17","article-title":"The Current State of Macrolide Resistance in Campylobacter spp.: Trends and Impacts of Resistance Mechanisms","volume":"83","author":"Bolinger","year":"2017","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_29","first-page":"e000195","article-title":"Fluoroquinolone resistance in Salmonella: Insights by whole-genome sequencing","volume":"4","author":"Cuypers","year":"2018","journal-title":"Microb. Genom."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.idc.2013.08.001","article-title":"Control of Neisseria gonorrhoeae in the era of evolving antimicrobial resistance","volume":"27","author":"Barbee","year":"2013","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_31","first-page":"e000214","article-title":"The return of Pfeiffer\u2019s bacillus: Rising incidence of ampicillin resistance in Haemophilus influenzae","volume":"4","author":"Heinz","year":"2018","journal-title":"Microb. Genom."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bose, P., Chowdhury, G., Halder, G., Ghosh, D., Deb, A.K., Kitahara, K., Miyoshi, S.I., Morita, M., Ramamurthy, T., and Dutta, S. (2024). Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011\u20132019. PLoS Negl. Trop. Dis., 18.","DOI":"10.1371\/journal.pntd.0011964"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14756366.2017.1344235","article-title":"Beta-lactamase database (BLDB)\u2014structure and function","volume":"32","author":"Naas","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shurina, B.A., and Page, R.C. (2021). Structural Comparisons of Cefotaximase (CTX-M-ase) Sub Family 1. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.688509"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1128\/AAC.37.5.962","article-title":"Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa","volume":"37","author":"Nordmann","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.50.4.1610-1611.2006","article-title":"First isolation of blaIMI-2 in an Enterobacter cloacae clinical isolate from China","volume":"50","author":"Yu","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","article-title":"The urgent need for metallo-beta-lactamase inhibitors: An unattended global threat","volume":"22","author":"Mojica","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/CMR.18.2.306-325.2005","article-title":"Metallo-beta-lactamases: The quiet before the storm?","volume":"18","author":"Walsh","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.46.1.1-11.2002","article-title":"Plasmid-determined AmpC-type beta-lactamases","volume":"46","author":"Philippon","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1021\/ar300327a","article-title":"Class D beta-lactamases: A reappraisal after five decades","volume":"46","author":"Leonard","year":"2013","journal-title":"Acc. Chem. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1128\/AAC.00218-07","article-title":"Interactions of ceftobiprole with beta-lactamases from molecular classes A to D","volume":"51","author":"Queenan","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Carcione, D., Siracusa, C., Sulejmani, A., Leoni, V., and Intra, J. (2021). Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. Antibiotics, 10.","DOI":"10.3390\/antibiotics10080995"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: The versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","article-title":"The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria","volume":"9","author":"Nordmann","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1128\/AAC.00107-16","article-title":"Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1099\/jmm.0.008094-0","article-title":"Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency","volume":"58","author":"Wang","year":"2009","journal-title":"J. Med. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s15010-019-01291-9","article-title":"AmpC beta-lactamase-producing Enterobacterales: What a clinician should know","volume":"47","author":"Meini","year":"2019","journal-title":"Infection"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hammoudi Halat, D., and Ayoub Moubareck, C. (2020). The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria. Antibiotics, 9.","DOI":"10.3390\/antibiotics9040186"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CMR.00117-13","article-title":"OXA beta-lactamases","volume":"27","author":"Evans","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1128\/AAC.02522-13","article-title":"Class D beta-lactamases: Are they all carbapenemases?","volume":"58","author":"Antunes","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1473-3099(11)70056-1","article-title":"Metallo-beta-lactamases: A last frontier for beta-lactams?","volume":"11","author":"Cornaglia","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/jac\/dkx131","article-title":"Acinetobacter baumannii transfers the blaNDM-1 gene via outer membrane vesicles","volume":"72","author":"Chatterjee","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/14656566.2015.994504","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal infections","volume":"16","author":"Eckmann","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): A randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.02286-15","article-title":"In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"106318","DOI":"10.1016\/j.ijantimicag.2021.106318","article-title":"Cefepime\/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria","volume":"57","author":"Mushtaq","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/ja0288338","article-title":"Nanomolar inhibitors of AmpC beta-lactamase","volume":"125","author":"Morandi","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11361","DOI":"10.1021\/bi700792a","article-title":"Overcoming resistance to beta-lactamase inhibitors: Comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244","volume":"46","author":"Thomson","year":"2007","journal-title":"Biochemistry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"35528","DOI":"10.1074\/jbc.M501251200","article-title":"Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition","volume":"280","author":"Sulton","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., Jubeh, B., and Karaman, R. (2020). Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules, 25.","DOI":"10.3390\/molecules25061340"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e01816-19","DOI":"10.1128\/AAC.01816-19","article-title":"Ceftazidime-Avibactam Resistance Associated with Increased bla(KPC-3) Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae","volume":"64","author":"Coppi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): A potent new class of non-beta-lactam beta-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Watkins, R.R., Papp-Wallace, K.M., Drawz, S.M., and Bonomo, R.A. (2013). Novel beta-lactamase inhibitors: A therapeutic hope against the scourge of multidrug resistance. Front. Microbiol., 4.","DOI":"10.3389\/fmicb.2013.00392"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.11.5.852","article-title":"Clavulanic acid: A beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus","volume":"11","author":"Reading","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1093\/jac\/dkt240","article-title":"Population pharmacokinetics and dosing simulations of amoxicillin\/clavulanic acid in critically ill patients","volume":"68","author":"Carlier","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cmi.2019.11.028","article-title":"Oral amoxicillin and amoxicillin-clavulanic acid: Properties, indications and usage","volume":"26","author":"Huttner","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.amjoto.2006.06.007","article-title":"Amoxicillin-clavulanic acid-induced hepatitis","volume":"28","author":"Cundiff","year":"2007","journal-title":"Am. J. Otolaryngol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12232","article-title":"Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: Evaluation of the impact of renal impairment","volume":"77","author":"Soto","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_73","unstructured":"Peechakara, B.V., and Gupta, M. (2024). StatPearls, Treasure Island."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1469-0691.2007.01847.x","article-title":"Sulbactam-containing beta-lactamase inhibitor combinations","volume":"14","author":"Akova","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14787210.2019.1647781","article-title":"Pharmacokinetics-pharmacodynamics of beta-lactamase inhibitors: Are we missing the target?","volume":"17","author":"Monogue","year":"2019","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/00003495-199957050-00017","article-title":"Piperacillin\/tazobactam: An updated review of its use in the treatment of bacterial infections","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"key":"ref_77","unstructured":"(2012). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/17425255.2010.506187","article-title":"Pharmacokinetic evaluation of piperacillin-tazobactam","volume":"6","author":"Hayashi","year":"2010","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: Place in therapy","volume":"16","author":"Giacobbe","year":"2018","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2020.05.001","article-title":"Resistance to Novel beta-Lactam-beta-Lactamase Inhibitor Combinations: The \u201cPrice of Progress\u201d","volume":"34","author":"Mack","year":"2020","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e00174-18","DOI":"10.1128\/AAC.00174-18","article-title":"Relebactam Is a Potent Inhibitor of the KPC-2 beta-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae","volume":"62","author":"Barnes","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e00105-19","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent beta-Lactam-beta-Lactamase Inhibitor Combination","volume":"63","author":"Bethel","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e00514-19","DOI":"10.1128\/AAC.00514-19","article-title":"In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014\u20132015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/QCO.0000000000000600","article-title":"The role of new beta-lactamase inhibitors in gram-negative infections","volume":"32","author":"Vena","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"105925","DOI":"10.1016\/j.ijantimicag.2020.105925","article-title":"In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae","volume":"56","author":"Tselepis","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: A novel cephalosporin\/beta-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2378","article-title":"Imipenem-Cilastatin-Relebactam: A Novel beta-Lactam-beta-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections","volume":"40","author":"Smith","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e00672-19","DOI":"10.1128\/AAC.00672-19","article-title":"Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae","volume":"63","author":"Canver","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"ofaa054","DOI":"10.1093\/ofid\/ofaa054","article-title":"Evaluation of Renal Safety Between Imipenem\/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study","volume":"7","author":"Brown","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e00432-19","DOI":"10.1128\/AAC.00432-19","article-title":"Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC","volume":"63","author":"Barnes","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/jac\/dkx050","article-title":"WCK 5222 (cefepime\/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant beta-lactamases","volume":"72","author":"Sader","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e01576-17","DOI":"10.1128\/AAC.01576-17","article-title":"Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel beta-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii","volume":"62","author":"McLeod","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e01110-18","DOI":"10.1128\/AAC.01110-18","article-title":"New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1093\/jac\/dkad242","article-title":"Imipenem\/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: A novel modelling approach for time-dependent killing","volume":"78","author":"Fratoni","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgar.2022.07.006","article-title":"In vitro and in vivo activities of a novel beta-lactamase inhibitor combination imipenem\/XNW4107 against recent clinical Gram-negative bacilli from China","volume":"31","author":"Li","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.idc.2016.02.007","article-title":"New beta-Lactamase Inhibitors in the Clinic","volume":"30","author":"Bonomo","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid beta-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2018.08.007","article-title":"What\u2019s new in the treatment of multidrug-resistant gram-negative infections?","volume":"93","author":"Mo","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e01963-19","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e0105321","DOI":"10.1128\/AAC.01053-21","article-title":"Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous beta-Lactamase Inhibitor","volume":"65","author":"Dowell","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QCO.0000000000000885","article-title":"Novel agents in development for multidrug-resistant Gram-negative infections: Potential new options facing multiple challenges","volume":"35","author":"Arya","year":"2022","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1060736","DOI":"10.3389\/fgene.2022.1060736","article-title":"Biochemical exploration of beta-lactamase inhibitors","volume":"13","author":"Arer","year":"2022","journal-title":"Front. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e00130-20","DOI":"10.1128\/AAC.00130-20","article-title":"Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e00212-20","DOI":"10.1128\/AAC.00212-20","article-title":"Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases","volume":"64","author":"Lomovskaya","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e0087922","DOI":"10.1128\/aac.00879-22","article-title":"Intrinsic Antibacterial Activity of Xeruborbactam In Vitro: Assessing Spectrum and Mode of Action","volume":"66","author":"Sun","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1021\/acs.jmedchem.9b01976","article-title":"Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-beta-lactamases","volume":"63","author":"Hecker","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lomovskaya, O., Tsivkovski, R., Sun, D., Reddy, R., Totrov, M., Hecker, S., Griffith, D., Loutit, J., and Dudley, M. (2021). QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.697180"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Chaudhry, S.B., Veve, M.P., and Wagner, J.L. (2019). Cephalosporins: A Focus on Side Chains and beta-Lactam Cross-Reactivity. Pharmacy, 7.","DOI":"10.3390\/pharmacy7030103"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Principe, L., Lupia, T., Andriani, L., Campanile, F., Carcione, D., Corcione, S., De Rosa, F.G., Luzzati, R., Stroffolini, G., and Steyde, M. (2022). Microbiological, Clinical, and PK\/PD Features of the New Anti-Gram-Negative Antibiotics: Beta-Lactam\/beta-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians. Pharmaceuticals, 15.","DOI":"10.3390\/ph15040463"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/phar.2502","article-title":"Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy","volume":"41","author":"Kalaria","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e01484-18","DOI":"10.1128\/AAC.01484-18","article-title":"Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment","volume":"63","author":"Preston","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bcp.14204","article-title":"Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin","volume":"86","author":"Bhagunde","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1128\/AAC.39.12.2593","article-title":"Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: Mutations, specificity, and three-dimensional structure","volume":"39","author":"Knox","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2017.11.002","article-title":"An update on beta-lactamase inhibitor discovery and development","volume":"36","author":"Docquier","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/acsinfecdis.7b00113","article-title":"Reversibility of Covalent, Broad-Spectrum Serine beta-Lactamase Inhibition by the Diazabicyclooctenone ETX2514","volume":"3","author":"Shapiro","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e01386-19","DOI":"10.1128\/AAC.01386-19","article-title":"Suppression of \u03b2-Lactam Resistance by Aspergillomarasmine A Is Influenced by both the Metallo-\u03b2-Lactamase Target and the Antibiotic Partner","volume":"64","author":"Rotondo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"E3745","DOI":"10.1073\/pnas.1601368113","article-title":"Cross-class metallo-\u03b2-lactamase inhibition by bisthiazolidines reveals multiple binding modes","volume":"113","author":"Hinchliffe","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/acs.biochem.7b01299","article-title":"Structural and Kinetic Studies of the Potent Inhibition of Metallo-\u03b2-lactamases by 6-Phosphonomethylpyridine-2-carboxylates","volume":"57","author":"Hinchliffe","year":"2018","journal-title":"Biochemistry"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e00074-18","DOI":"10.1128\/AAC.00074-18","article-title":"Discovery of a Novel Metallo-beta-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae","volume":"62","author":"Everett","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1128\/AAC.04146-14","article-title":"Activity of Ceftazidime-Avibactam Combination in Checkerboard Assays","volume":"59","author":"Berkhout","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Voracova, M., Zore, M., Yli-Kauhaluoma, J., and Kiuru, P. (2023). Harvesting phosphorus-containing moieties for their antibacterial effects. Bioorg Med. Chem., 96.","DOI":"10.1016\/j.bmc.2023.117512"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1021\/bi900807e","article-title":"Inhibition of class A and C beta-lactamases by diaroyl phosphates","volume":"48","author":"Majumdar","year":"2009","journal-title":"Biochemistry"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"16121","DOI":"10.1021\/bi051719s","article-title":"Inhibition of class D beta-lactamases by diaroyl phosphates","volume":"44","author":"Majumdar","year":"2005","journal-title":"Biochemistry"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1126\/science.2814513","article-title":"Inhibition of a class C beta-lactamase by a specific phosphonate monoester","volume":"246","author":"Pratt","year":"1989","journal-title":"Science"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"115473","DOI":"10.1016\/j.ejmech.2023.115473","article-title":"Metal binding pharmacophore click-derived discovery of new broad-spectrum metallo-beta-lactamase inhibitors","volume":"257","author":"Yan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/8.suppl_E.1","article-title":"Monobactams\u2014monocyclic \u03b2-lactam antibiotics produced by bacteria","volume":"8","author":"Sykes","year":"1981","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/jac\/dkt434","article-title":"A kinetic analysis of the inhibition of FOX-4 beta-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic beta-lactams and carbapenems","volume":"69","author":"Mallo","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.bmcl.2011.05.065","article-title":"Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712","volume":"21","author":"Chen","year":"2011","journal-title":"Bioorg Med. Chem. Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/AAC.43.8.1895","article-title":"In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor","volume":"43","author":"Nishida","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/AAC.01525-09","article-title":"In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli","volume":"54","author":"Page","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/dkr013","article-title":"In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii","volume":"66","author":"Russo","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1568026013395524","article-title":"Siderophore-antibiotic conjugates used as trojan horses against Pseudomonas aeruginosa","volume":"1","author":"Budzikiewicz","year":"2001","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1021\/acs.jmedchem.7b00407","article-title":"Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-beta-lactamase-1","volume":"60","author":"Chen","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the beta-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ja.2010.20","article-title":"Inhibition of metallo-beta-lactamases by pyridine monothiocarboxylic acid analogs","volume":"63","author":"Roll","year":"2010","journal-title":"J. Antibiot."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1080\/13880209.2022.2127791","article-title":"In vitro and in silico beta-lactamase inhibitory properties and phytochemical profile of Ocimum basilicum cultivated in central delta of Egypt","volume":"60","author":"Shoeib","year":"2022","journal-title":"Pharm. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.112.193847","article-title":"Carnosol and carnosic acids from Salvia officinalis inhibit microsomal prostaglandin E2 synthase-1","volume":"342","author":"Bauer","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"581001","DOI":"10.3389\/fphar.2020.581001","article-title":"Discovery of a Novel Natural Allosteric Inhibitor That Targets NDM-1 Against Escherichia coli","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.phymed.2009.08.003","article-title":"Beta-lactamase inhibitory component from the roots of Fissistigma cavaleriei","volume":"17","author":"Yang","year":"2010","journal-title":"Phytomedicine"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/np50107a016","article-title":"SB-202742, a novel beta-lactamase inhibitor isolated from Spondias mombin","volume":"57","author":"Coates","year":"1994","journal-title":"J. Nat. Prod."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1128\/AAC.46.7.2266-2268.2002","article-title":"Inhibition of penicillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of penicillin against penicillinase-producing Staphylococcus aureus","volume":"46","author":"Zhao","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e00127-21","DOI":"10.1128\/AEM.00127-21","article-title":"Cranberry-Derived Proanthocyanidins Potentiate beta-Lactam Antibiotics against Resistant Bacteria","volume":"87","author":"Gallique","year":"2021","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nature13445","article-title":"Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance","volume":"510","author":"King","year":"2014","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s12010-009-8656-2","article-title":"Inhibition of beta-lactamase by 1,4-naphthalenedione from the plant Holoptelea integrifolia","volume":"160","author":"Vinod","year":"2010","journal-title":"Appl. Biochem. Biotechnol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/3\/260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:13:59Z","timestamp":1760105639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/3\/260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":152,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["antibiotics13030260"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13030260","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}